Government Launches Mission COVID Suraksha to accelerate Indian COVID-19 Vaccine Development


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Government Launches Mission COVID Suraksha to accelerate Indian COVID-19 Vaccine Development
Mission COVID Suraksha is the targeted effort to enable the development of indigenous, affordable and accessible vaccines for the country and will complement the National Mission of AtmanirbharBharat

The Government of India has announced the third stimulus package of Rs. 900 Crore for the Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission. This grant will be provided to the Department of Biotechnology (DBT) for Research & Development of Indian COVID-19 vaccines.

The COVID-19 Vaccine development Mission with end-to-end focus from preclinical development through clinical development and manufacturing and regulatory facilitation for deployment would consolidate all available and funded resources towards accelerated product development. This will help accelerate the development of approx. 5-6 vaccine candidates and ensure that these are brought closer to licensure and introduction in the market for consideration of regulatory authorities for introduction in public health systems, to combat further spread of COVID infection.

The important objectives of the fund will be accelerating pre-clinical& clinical development; licensure of COVID-19 vaccine candidates that are currently in clinical stages or ready to enter the clinical stage of development, establishing clinical trial sites, and strengthening the existing immunoassay laboratories, central laboratories and suitable facilities for animal studies, production facilities and other testing facilities to support COVID-19 vaccine development. The other important objective will be supporting the development of common harmonized protocols, training, data management systems, regulatory submissions, internal and external quality management systems and accreditations. Capabilities for process development, cell line development and manufacturing of GMP batches for animal toxicology studies and clinical trials will also be supported under the Mission. A key element will be the development of suitable Target Product Profile so that vaccines being introduced through the mission have preferred characteristics applicable to India.

Led by Department of Biotechnology and implemented by a dedicated Mission Implementation Unit at Biotechnology Industry Research Assistance Council (BIRAC), the existing activities under National Bio Pharma Mission (NBM) and Ind-CEPI Mission will provide complementary strengths to this Mission.

Phase-I of the COVID Suraksha Mission has been allotted Rs.900 Crore for a period of 12 months.

A total of 10 vaccine candidates have been supported by Department of Biotechnology so far at both academia and industry and as on date, 5 vaccine candidates are in human trials including the Russian Vaccine Sputnik-V with at least 3 more in advanced stages of preclinical to enter human trials shortly.

Dr RenuSwarup, Secretary Department of Biotechnology, Ministry of Science & Technology and Chairperson BIRAC said, “Mission COVID Suraksha is our targeted effort to enable the development of indigenous, affordable and accessible vaccines for our country and will complement the National Mission of AtmanirbharBharat”.“India has exhibited enormous strength in vaccine manufacturing and through this National COVID Vaccine Mission, we are confident that our vaccine manufacturers will develop affordable and accessible vaccine not only for India but the world”, she added.

Tags : #GovernmentofIndia #LatestCOVIDNews30thNov #FightAgainstCorona #AtmanirbharBharat #AffordableVaccine #LatestPharmaNews30thNov #DepartmentofBiotechnology #MissionCOVIDSuraksha #LatestNewsonCOVIDVaccine30thNov

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026